Lyell Immunopharma (LYEL) Income from Continuing Operations (2020 - 2026)
Lyell Immunopharma (LYEL) reported Income from Continuing Operations of 103216000.0 for Q1 2026, up 19.91% on a YoY basis from 86074330.17 in Q1 2025, and up 28.67% sequentially from 144693000.0 in Q4 2025.
Lyell Immunopharma (LYEL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Income from Continuing Operations data on file, last reported at 103216000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 19.91% year-over-year to 103216000.0; the trailing twelve-month figure through Mar 2026 stood at 465544000.0 (up 50.67% YoY), and the FY2025 full-year result was 286543000.0, up 60.08% from the prior year.
- Income from Continuing Operations advanced to 103216000.0 in Q1 2026, from 144693000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 70050000.0 in Q3 2023 to a low of 561056000.0 in Q4 2024.
- A 5-year average of 160089882.35 and a median of 128883000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 216.19% in 2022 and surged 74.21% in 2025, its largest moves.
- Tracing LYEL's Income from Continuing Operations over 5 years: stood at 192519000.0 in 2022, then slumped by 59.38% to 306841000.0 in 2023, then sank by 82.85% to 561056000.0 in 2024, then surged by 74.21% to 144693000.0 in 2025, then rose by 28.67% to 103216000.0 in 2026.
- Business Quant data shows LYEL's Income from Continuing Operations at 103216000.0 in Q1 2026, 144693000.0 in Q4 2025, and 102168000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - | -103.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -103.22 Mn |
| Dec 31, 2025 | -144.69 Mn |
| Sep 30, 2025 | -102.17 Mn |
| Jun 30, 2025 | -115.47 Mn |
| Mar 31, 2025 | -128.88 Mn |
| Dec 31, 2024 | -561.06 Mn |
| Sep 30, 2024 | -124.41 Mn |
| Jun 30, 2024 | -129.48 Mn |
| Mar 31, 2024 | -74.91 Mn |
| Dec 31, 2023 | -306.84 Mn |
| Sep 30, 2023 | -70.05 Mn |
| Jun 30, 2023 | -90.81 Mn |
| Mar 31, 2023 | -83.31 Mn |
| Dec 31, 2022 | -192.52 Mn |
| Sep 30, 2022 | -188.38 Mn |
| Jun 30, 2022 | -129.98 Mn |
| Mar 31, 2022 | -175.37 Mn |
| Dec 31, 2021 | -176.32 Mn |
| Sep 30, 2021 | -60.65 Mn |
| Jun 30, 2021 | -173.90 Mn |